These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11531258)

  • 41. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
    Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
    J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
    Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
    Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines.
    Kitahara K; Yasui W; Yokozaki H; Semba S; Hamamoto T; Hisatsugu T; Tahara E
    J Exp Ther Oncol; 1996 Jan; 1(1):7-12. PubMed ID: 9414383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of p63 amplification and overexpression in lung cancer development.
    Massion PP; Taflan PM; Rahman SM; Yildiz P; Shyr Y; Carbone DP; Gonzalez AL
    Chest; 2004 May; 125(5 Suppl):102S. PubMed ID: 15136437
    [No Abstract]   [Full Text] [Related]  

  • 45. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran.
    Biramijamal F; Allameh A; Mirbod P; Groene HJ; Koomagi R; Hollstein M
    Cancer Res; 2001 Apr; 61(7):3119-23. PubMed ID: 11306496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma.
    Ho GH; Calvano JE; Bisogna M; Abouezzi Z; Borgen PI; Cordón-Cardó C; van Zee KJ
    Breast Cancer Res Treat; 2001 Feb; 65(3):225-32. PubMed ID: 11336244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allelic deletions of cell growth regulators during progression of bladder cancer.
    Primdahl H; von der Maase H; Christensen M; Wolf H; Orntoft TF
    Cancer Res; 2000 Dec; 60(23):6623-9. PubMed ID: 11118045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas.
    Esteve A; Martel-Planche G; Sylla BS; Hollstein M; Hainaut P; Montesano R
    Int J Cancer; 1996 May; 66(3):301-4. PubMed ID: 8621247
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China.
    Cao W; Chen X; Dai H; Wang H; Shen B; Chu D; McAfee T; Zhang ZF
    Cancer; 2004 Aug; 101(4):834-44. PubMed ID: 15305417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SSRP1 functions as a co-activator of the transcriptional activator p63.
    Zeng SX; Dai MS; Keller DM; Lu H
    EMBO J; 2002 Oct; 21(20):5487-97. PubMed ID: 12374749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
    Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
    J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 mutational spectrum of esophageal carcinomas from five different geographical locales in China.
    Lung ML; Chan WC; Zong YS; Tang CM; Fok CL; Wong KT; Chan LK; Lau KW
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):277-84. PubMed ID: 8722219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma cell lines.
    Xu L; Davidson BJ; Murty VV; Li RG; Sacks PG; Garin-Chesa P; Schantz SP; Chaganti RS
    Int J Cancer; 1994 Nov; 59(3):383-7. PubMed ID: 7927946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas.
    Esteve A; Lehman T; Jiang W; Weinstein IB; Harris CC; Ruol A; Peracchia A; Montesano R; Hollstein M
    Mol Carcinog; 1993; 8(4):306-11. PubMed ID: 8280379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
    Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
    Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.
    Wiencke JK; Aldape K; McMillan A; Wiemels J; Moghadassi M; Miike R; Kelsey KT; Patoka J; Long J; Wrensch M
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1774-83. PubMed ID: 16030116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis.
    Nindl I; Gottschling M; Krawtchenko N; Lehmann MD; Röwert-Huber J; Eberle J; Stockfleth E; Forschner T
    Br J Dermatol; 2007 May; 156 Suppl 3():34-9. PubMed ID: 17488404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.